Home > Companies > Shomerosh
Last Update 29.6.2022Edit Profile
Shomerosh logo
Shomerosh
App for Detecting Preclinical Alzheimers Disease
Non Visible
 
https://www.claramind.com/

About

Shomerosh is a free, noninvasive, user-friendly app designed to detect Alzheimers disease at the preclinical stage, when the neural pathology may still be reversible. The predictive model is based on a novel personalized cognitive task that can be completed from home and is sensitive to the very early stages of Alzheimers disease.

Founded

9/2016

Business models

B2B, B2C

Employees

1-10

Product stage

Alpha

Products

Clara

Geographic markets

-

Funding

Total Funding

$200K

Last Funding

$200K

Funding Stage

Bootstrapped

Total Rounds

1

Investors

0

News

  (0)

The Team

(1)
LG
Lidor Gazit
Neuroscientist

Company Lifecycle

Event View
Timeline View

Public Offerings & Exits

Private Equity Funding

Mergers and Acquisitions

Others

Academic Techonology
Sep 2016
Medical Devices App that identifies early-stage mild cognitive impairment and Alzheimer's

Use Cases (0)

Media gallery

(0)

Locations

Israel

32 Shocken Street, Tel Aviv

Offices Abroad

Sector

Life Sciences & HealthTech
Digital Health
Diagnostics

Core Technology

Artificial Intelligence
Machine Learning
Platforms & Interfaces
Mobile

Target Industry

Healthcare & Life Sciences
Life Sciences
Pharmaceuticals
Healthcare
Patients
Providers

Tags

(12)
early-detection diagnostics mobile-applications population-health-management digital-healthcare machine-learning degenerative-diseases neurology aging-population artificial-intelligence alzheimers-disease personalization

Target Markets

(2)
healthcare-providers pharma-companies

Notes

Content Writer
undefined
BI Verification
undefined
Phone Number
undefined
Israel Register ID
undefined
Confidence Score
undefined
Missing Fields
undefined
Profile Creator
undefined
Profile Update
undefined
undefined
Data and visuals presented here may not be used without the written consent of Start-Up Nation Finder.
Copyright © 2022 Terms of Use Privacy Policy